BenevolentAI
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in delivered drug candidate within years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
21 of 38
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
January 2023
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression | BenevolentAI
Investor Presentation
October 2022
ben results and progress to date novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in only years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Investor Day
September 2022
ben results and progress to date novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in only years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Investor Presentation
June 2022
ben results and progress to date | BenevolentAI
Related slides by other companies
Exscientia
Investor Presentation
August 2023
why are our clinical candidates different | Exscientia
argenx SE
Investor Presentation
March 2023
targets at junction of classical and pathways | argenx SE
Exscientia
Investor Presentation
July 2023
why are our clinical candidates different | Exscientia
Erasca
Investor Presentation
January 2024
clinical development plan generates multiple ways to win for patients | Erasca
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io